ES2123829T3 - Derivados de 3-(5-tetrazolil-bencil)amino-piperidina y antagonistas de las taquiquininas. - Google Patents

Derivados de 3-(5-tetrazolil-bencil)amino-piperidina y antagonistas de las taquiquininas.

Info

Publication number
ES2123829T3
ES2123829T3 ES94927627T ES94927627T ES2123829T3 ES 2123829 T3 ES2123829 T3 ES 2123829T3 ES 94927627 T ES94927627 T ES 94927627T ES 94927627 T ES94927627 T ES 94927627T ES 2123829 T3 ES2123829 T3 ES 2123829T3
Authority
ES
Spain
Prior art keywords
sub
sup
atom
hydrogen
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94927627T
Other languages
English (en)
Inventor
Duncan Robert Armour
Brian Evans
Gerard Martin Paul Giblin
Michael Menteith Hann
Tania Hubbard
Xiao-Qing Lewell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939319606A external-priority patent/GB9319606D0/en
Priority claimed from GB9326583A external-priority patent/GB9326583D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2123829T3 publication Critical patent/ES2123829T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A DERIVADOS DE LA PIPERIDINA DE LA FORMULA (I), EN LA QUE R{SUP,1} ES UN GRUPO ALCOXI C{SUB,14}; R{SUP,2} ES LA FORMULA (A); R{SUP,3} ES UN ATOMO DE HIDROGENO O UNO DE HALOGENO; R{SUP,4} Y R{SUP,5} PUEDE REPRESENTAR CADA UNO, INDEPENDIENTEMENTE, UN ATOMO DE HIDROGENO O UNO DE HALOGENO, O UN GRUPO ALQUILO C{SUB,1-4}, UNO ALCOXI C{SUB,1-4} O UNO TRIFLUOROMETILO; R{SUP,6} ES UN ATOMO DE HIDROGENO, UN GRUPO ALQUILO C{SUB,1-4}, UNO (CH{SUB,2}){SUB,M}CICLOPROPILO, UNO S(O){SUB,N}ALQUILO C{SUB,1-4}, UNO FENILO, UNO NR{SUP,7}R{SUP,8}, UNO CH{SUB,2}C(O)CF{SUB,3} O UNO TRIFLUOROMETILO; R{SUP,7} Y R{SUP,8} PUEDE REPRESENTAR CADA UNO, INDEPENDIENTEMENTE, UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO C{SUB,1-4} O UNO ACILO; X REPRESENTA CERO O 1; N REPRESENTA CERO, 1 O 2; M REPRESENTA CERO O 1; Y A LAS SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS; A PROCESOS PARA SU PREPARACION; Y A SU USO EN EL TRATAMIENTO DE ESTADOS EN LOS QUE INTERVIENEN TAQUIQUININAS.
ES94927627T 1993-09-22 1994-09-20 Derivados de 3-(5-tetrazolil-bencil)amino-piperidina y antagonistas de las taquiquininas. Expired - Lifetime ES2123829T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939319606A GB9319606D0 (en) 1993-09-22 1993-09-22 Chemical compounds
GB9326583A GB9326583D0 (en) 1993-12-31 1993-12-31 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2123829T3 true ES2123829T3 (es) 1999-01-16

Family

ID=26303560

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94927627T Expired - Lifetime ES2123829T3 (es) 1993-09-22 1994-09-20 Derivados de 3-(5-tetrazolil-bencil)amino-piperidina y antagonistas de las taquiquininas.

Country Status (29)

Country Link
US (2) US5703240A (es)
EP (1) EP0720609B1 (es)
JP (2) JP2865872B2 (es)
CN (1) CN1061041C (es)
AP (1) AP495A (es)
AT (1) ATE173255T1 (es)
AU (1) AU681190B2 (es)
BG (1) BG62169B1 (es)
CA (1) CA2172529A1 (es)
CO (1) CO4290298A1 (es)
CZ (1) CZ285479B6 (es)
DE (1) DE69414590T2 (es)
DK (1) DK0720609T3 (es)
ES (1) ES2123829T3 (es)
FI (1) FI961270A7 (es)
GR (1) GR3029354T3 (es)
HR (1) HRP940575B1 (es)
HU (1) HU217428B (es)
IL (1) IL111002A (es)
IS (1) IS4208A (es)
NO (1) NO307830B1 (es)
NZ (1) NZ273614A (es)
OA (1) OA10576A (es)
PE (1) PE18295A1 (es)
PL (1) PL179585B1 (es)
SI (1) SI0720609T1 (es)
SK (1) SK280901B6 (es)
UA (1) UA44711C2 (es)
WO (1) WO1995008549A1 (es)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317987D0 (en) * 1993-08-26 1993-10-13 Glaxo Group Ltd Chemical compounds
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
JP3925662B2 (ja) * 1995-01-12 2007-06-06 グラクソ，グループ，リミテッド タキキニンアンタゴニスト活性を有するピペリジン誘導体
GB9505692D0 (en) * 1995-03-21 1995-05-10 Glaxo Group Ltd Chemical compounds
GB9513117D0 (en) * 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) * 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
AU714542B2 (en) * 1996-06-26 2000-01-06 Warner-Lambert Company Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
US6100256A (en) * 1996-12-02 2000-08-08 Merck Sharp & Dohme Ltd. Use of NK-1 receptors antagonists for treating schizophrenic disorders
WO1998024439A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating severe anxiety disorders
CA2273853A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating cognitive disorders
US6613765B1 (en) 1996-12-02 2003-09-02 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating major depressive disorders
AU736042B2 (en) * 1996-12-02 2001-07-26 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
AU731349B2 (en) * 1996-12-02 2001-03-29 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating sexual dysfunctions
EP0942729B1 (en) * 1996-12-02 2004-09-01 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating stress disorders
JP2001504853A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 物質使用障害の治療のためのｎｋ−１受容体拮抗薬の使用
CA2273807A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating schizophrenic disorders
EP0942730A1 (en) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating bipolar disorders
EP0942732B1 (en) * 1996-12-02 2004-11-17 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating movement disorders
US6114315A (en) * 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
WO1998024438A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating major depressive disorders
US5861417A (en) * 1996-12-19 1999-01-19 Hoechst Marion Roussel, Inc. Heterocyclic substituted pyrrolidine amide derivatives
EP0977572A1 (en) * 1997-04-24 2000-02-09 Merck Sharp & Dohme Ltd. Use of nk-1 receptor antagonists for treating eating disorders
US6214846B1 (en) 1997-06-27 2001-04-10 Merck Sharp & Dohme Limited Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
CA2298777A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating mania
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
WO1999007375A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
GB9723544D0 (en) * 1997-11-07 1998-01-07 Merck Sharp & Dohme Therapeutic agents
US6156749A (en) * 1997-12-01 2000-12-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating movement disorders
US6087348A (en) * 1997-12-01 2000-07-11 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating stress disorders
US6271230B1 (en) 1997-12-01 2001-08-07 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating cognitive disorders
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
DE60042446D1 (de) * 1999-02-18 2009-08-06 Novasearch Ag Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
JP2001039954A (ja) * 1999-05-24 2001-02-13 Tomono Agrica Co Ltd ヘテロ環誘導体
WO2001032625A1 (en) 1999-11-03 2001-05-10 Du Pont Pharmaceuticals Company Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
JP5132864B2 (ja) 2000-07-11 2013-01-30 アルバニー モレキュラー リサーチ， インコーポレイテッド ４−フェニル置換テトラヒドロイソキノリンおよびその使用方法
AU2001292320A1 (en) * 2000-10-02 2002-04-15 Tanabe Seiyaku Co., Ltd. Benzylamine compound, process for producing the same, and intermediate therefor
WO2002064022A2 (en) * 2001-02-14 2002-08-22 Duke University Therapy for cerebral vasospasm
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
EP1558599A4 (en) * 2002-10-30 2007-06-27 Merck & Co Inc HETEROARYLPIPERIDINE MODULATORS DERCHEMOKIN RECEPTORACTIVITY
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
JP4710608B2 (ja) * 2003-08-01 2011-06-29 東洋紡績株式会社 アルコキシ−テトラゾール−１−イル−ベンズアルデヒド化合物およびその製造方法
CN1580283A (zh) * 2003-08-13 2005-02-16 清华大学 一种检测核酸分子的方法
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
AU2005274927B2 (en) 2004-07-15 2011-11-03 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
JP2006137691A (ja) * 2004-11-11 2006-06-01 Toyo Kasei Kogyo Co Ltd ２−アルコキシ−５−テトラゾリル−ベンズアルデヒド化合物の製造方法
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
JP2010516731A (ja) * 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
CA2963784A1 (en) 2007-06-08 2008-12-18 Mannkind Corporation Ire-1.alpha. inhibitors
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2310369A4 (en) * 2008-06-24 2014-02-19 Valeant Pharmaceuticals Int BENZYL OXYANILID DERIVATIVES SUITABLE AS SODIUM CHANNEL MODULATORS
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2699567A1 (en) 2011-04-21 2014-02-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
EP2935263B1 (en) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
IL271464B2 (en) 2017-06-30 2024-08-01 Chase Therapeutics Corp NK-1 antagonist compositions and methods for use in the treatment of depression
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3758688B1 (en) 2018-02-26 2024-03-27 Ospedale San Raffaele S.r.l. Nk-1 antagonists for use in the treatment of ocular pain
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP4117673A1 (en) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Treatment of stem cell deficiency
CN117623228B (zh) * 2023-12-07 2025-12-02 江西赣锋锂业集团股份有限公司 一种四氢铝锂的制备方法
CN120441539A (zh) * 2024-02-08 2025-08-08 上海数因信科智能科技有限公司 四唑类化合物、其药物组合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
US5332817A (en) * 1990-01-04 1994-07-26 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
HU224443B1 (hu) * 1991-06-20 2005-09-28 Pfizer Inc. Fluor-alkoxi-benzaldehid-származékok
EP0675886B1 (en) * 1992-12-10 2000-07-05 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður

Also Published As

Publication number Publication date
EP0720609B1 (en) 1998-11-11
HU217428B (hu) 2000-01-28
EP0720609A1 (en) 1996-07-10
AP495A (en) 1996-05-28
UA44711C2 (uk) 2002-03-15
SK280901B6 (sk) 2000-09-12
DE69414590D1 (de) 1998-12-17
CN1061041C (zh) 2001-01-24
NO307830B1 (no) 2000-06-05
CO4290298A1 (es) 1996-04-17
FI961270A7 (fi) 1996-05-03
SI0720609T1 (en) 1999-02-28
US5843966A (en) 1998-12-01
OA10576A (en) 2002-06-03
PE18295A1 (es) 1995-07-27
AU7697494A (en) 1995-04-10
JPH11106341A (ja) 1999-04-20
PL313619A1 (en) 1996-07-08
AU681190B2 (en) 1997-08-21
HK1004219A1 (en) 1998-11-20
CZ285479B6 (cs) 1999-08-11
HRP940575A2 (en) 1997-02-28
JP2865872B2 (ja) 1999-03-08
AP9400671A0 (en) 1994-10-31
CA2172529A1 (en) 1995-03-30
ATE173255T1 (de) 1998-11-15
CZ83096A3 (en) 1996-09-11
CN1135218A (zh) 1996-11-06
DK0720609T3 (da) 1999-07-26
WO1995008549A1 (en) 1995-03-30
FI961270A0 (fi) 1996-03-19
DE69414590T2 (de) 1999-04-15
BG100487A (bg) 1996-12-31
IL111002A0 (en) 1994-11-28
NO961156D0 (no) 1996-03-21
US5703240A (en) 1997-12-30
SK38396A3 (en) 1997-02-05
NO961156L (no) 1996-05-21
NZ273614A (en) 1997-09-22
IL111002A (en) 1998-09-24
HUT75648A (en) 1997-05-28
IS4208A (is) 1995-03-23
BG62169B1 (bg) 1999-04-30
PL179585B1 (pl) 2000-09-29
HU9600722D0 (en) 1996-05-28
JPH09505275A (ja) 1997-05-27
GR3029354T3 (en) 1999-05-28
HRP940575B1 (en) 2000-06-30

Similar Documents

Publication Publication Date Title
ES2162857T3 (es) Derivados fenilicos trisustituidos utilizados como inhibidores de fosfodiesterasa.
CO5630036A2 (es) Nuevos derivados indol con afinidad por el receptor 5-ht6
ES2054825T3 (es) Compuestos heterociclicos terapeuticos.
ES2066620T3 (es) Nuevos derivados de perhidroisoindol y su preparacion.
ES2123652T3 (es) 7-(2-aminoetil)-benzotiazolonas.
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
ES2160640T3 (es) Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos.
ES2055523T3 (es) Agentes antifungicos de triazol.
AR030507A1 (es) Compuesto de pirazolopiridina y los usos farmaceuticos del mismo
PA8431301A1 (es) Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion
KR900012911A (ko) 흥분성 아미노산 수용기 길항질 화합물
MX9505063A (es) Tetralina- e indano-1h-imidazoles.
MX9300786A (es) Compuestos hipolipidaemicos.
ES2150642T3 (es) Nuevos derivados piridinicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
DK0687268T3 (da) Spiroazacykliske derivater som substans P-antagonister
ES2046202T3 (es) Un procedimiento para preparar un analogo de distamicina a.
ES2188957T3 (es) N-(4-(heteroarilmetil)fenil)-heteroarilaminas.
ES2187983T3 (es) Derivados 1,2,3,4-tetrahidronaftaleno sustituidos.
ES2031876T3 (es) Un procedimiento para la preparacion de 5,6-dihidro-2-(fenil sustituido)-1,2,4,-triazin-3,5(2h,4h)-dionas.
AR006360A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion.
NO308248B1 (no) Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat
ES2106616T3 (es) Derivados de 11,21-bisfenilo-19-nor-pregnanos.
ES2140381T3 (es) Nuevas 4h-pirido-(1,2-a)pirimidin-4-onas disustituidas en 2,9.
AR029343A1 (es) USO DE UN ANTAGONISTA DE NMDA DE BAJA AFINIDAD PARA EL TRATAMIENTO DE LA DEPRESIoN
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 720609

Country of ref document: ES